GT Biopharma Initiates GTB-5550 Clinical Trial for B7-H3 Targeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy GTBP?
Source: PRnewswire
- Trial Initiation: On May 14, 2026, GT Biopharma announced the dosing of the first patient in its clinical trial for GTB-5550 targeting B7-H3, marking a significant advancement in the company's oncology pipeline and expected to drive further development.
- Innovative Dosing Method: GTB-5550 is the first TriKE to utilize subcutaneous dosing, which may enhance patient compliance and treatment efficacy compared to traditional continuous infusion therapies, thereby strengthening its competitive position in the market.
- Financial Stability: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, providing financial assurance during the clinical trial phase and boosting investor confidence.
- Increased Market Competition: The focus on B7-H3 as a tumor target has significantly intensified in 2026, with GTB-5550 standing out as the only NK cell engager currently dosing patients in clinical trials, highlighting its unique market positioning amidst growing competition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GTBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GTBP
Wall Street analysts forecast GTBP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.364
Low
8.00
Averages
8.00
High
8.00
Current: 0.364
Low
8.00
Averages
8.00
High
8.00
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GT Biopharma Initiates GTB-5550 Clinical Trial for B7-H3 Targeting
- Trial Initiation: On May 14, 2026, GT Biopharma announced the dosing of the first patient in its clinical trial for GTB-5550 targeting B7-H3, marking a significant advancement in the company's oncology pipeline and expected to drive further development.
- Innovative Dosing Method: GTB-5550 is the first TriKE to utilize subcutaneous dosing, which may enhance patient compliance and treatment efficacy compared to traditional continuous infusion therapies, thereby strengthening its competitive position in the market.
- Financial Stability: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, providing financial assurance during the clinical trial phase and boosting investor confidence.
- Increased Market Competition: The focus on B7-H3 as a tumor target has significantly intensified in 2026, with GTB-5550 standing out as the only NK cell engager currently dosing patients in clinical trials, highlighting its unique market positioning amidst growing competition.
See More
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
- Clinical Advancement: GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 dosing initiated on May 14, 2026, marking a significant milestone in NK cell therapy that is expected to enhance its market competitiveness.
- Innovative Platform: The company's second-generation TriKE platform is described as 10-40 times more potent than the first generation, focusing on activating NK cells through nanobody technology, thereby improving therapeutic efficacy and reducing side effects, further solidifying its position in immuno-oncology.
- Funding Influx: Cumulative funding into NK-focused biotech has exceeded $4.2 billion from 2020 to 2026, indicating strong investment enthusiasm and market potential, with GT Biopharma positioned to benefit from this trend as a key player.
- Market Outlook: North America is expected to capture 44% of the global NK cell therapy market by 2026, and GT Biopharma's clinical trials and financial status provide a solid foundation for growth in this rapidly evolving market.
See More
GT Biopharma Doses First Patient in GTB-5550 Clinical Trial
- Trial Launch: On May 14, 2026, GT Biopharma dosed the first patient in its Phase 1 trial for GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in cancer treatment, particularly for patients with prostate, ovarian, and pancreatic cancers.
- FDA Approval: The IND application for GTB-5550 received FDA clearance in February 2026, with the trial structured as a basket trial prioritizing enrollment of advanced cancer patients who have failed prior therapies, demonstrating the company's commitment to addressing unmet medical needs.
- Strong Financial Position: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, thereby enhancing investor confidence in the progress of the clinical trial.
- Significant Market Potential: Targeting the estimated $362 billion global solid tumor market, the B7-H3 antigen has attracted multiple pharmaceutical companies, indicating a rapidly rising clinical translation potential in this competitive landscape.
See More
GT Biopharma Reports Q2 2026 Financial Results
- Widening Net Loss: GT Biopharma reported a net loss of approximately $2.8 million for Q2 2026, a significant increase from the $800,000 loss in the same quarter of 2025, indicating pressure on cost control and market competitiveness.
- Cash Position: As of March 31, 2026, the company had approximately $9 million in cash and cash equivalents, which is anticipated to be sufficient to fund operations through Q4 2026, demonstrating short-term liquidity management capabilities.
- Financial Transparency: The financial information released by GT Biopharma includes historical earnings data and Seeking Alpha’s Quant Rating, aimed at enhancing investor understanding of the company's financial status, although current performance is poor, the company is striving to improve transparency to attract investment.
- Market Outlook Challenges: While the company has a certain level of liquidity assurance, the ongoing losses may undermine investor confidence, necessitating effective measures to improve financial performance to maintain market competitiveness.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
GT Biopharma Launches Clinical Trial for B7-H3 Targeted Therapy
- Trial Launch: GT Biopharma announced on May 14, 2026, that the first patient has been dosed in its Phase 1 dose-escalation trial of GTB-5550, a therapy targeting B7-H3 in solid tumors, marking a significant advancement in the company's oncology efforts.
- Innovative Targeting Mechanism: GTB-5550 is the third TriKE® molecule from GT Biopharma, utilizing subcutaneous administration to enhance patient convenience, particularly in prostate cancer where B7-H3 is expressed in over 90% of metastatic castration-resistant tumors.
- Market Potential Emerges: The rising interest in B7-H3 as an oncology target is underscored by GT Biopharma's trial progress alongside other companies like Summit Therapeutics and IDEAYA, indicating broad applicability of this target in cancer treatment.
- Strengthened Industry Collaborations: The partnership between Summit Therapeutics and GSK further validates the market value of B7-H3, with the combination study of GSK's antibody drug and Summit's bispecific antibody expected to begin in mid-2026, providing positive signals for investors.
See More
GT Biopharma Initiates GTB-5550 Clinical Trial for B7-H3 Targeting
- Trial Initiation: On May 14, 2026, GT Biopharma announced the dosing of the first patient in its clinical trial for GTB-5550 targeting B7-H3, marking a significant advancement in the company's oncology pipeline and expected to drive further development.
- Innovative Dosing Method: GTB-5550 is the first TriKE to utilize subcutaneous dosing, which may enhance patient compliance and treatment efficacy compared to traditional continuous infusion therapies, thereby strengthening its competitive position in the market.
- Financial Stability: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, providing financial assurance during the clinical trial phase and boosting investor confidence.
- Increased Market Competition: The focus on B7-H3 as a tumor target has significantly intensified in 2026, with GTB-5550 standing out as the only NK cell engager currently dosing patients in clinical trials, highlighting its unique market positioning amidst growing competition.
See More
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
- Clinical Advancement: GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 dosing initiated on May 14, 2026, marking a significant milestone in NK cell therapy that is expected to enhance its market competitiveness.
- Innovative Platform: The company's second-generation TriKE platform is described as 10-40 times more potent than the first generation, focusing on activating NK cells through nanobody technology, thereby improving therapeutic efficacy and reducing side effects, further solidifying its position in immuno-oncology.
- Funding Influx: Cumulative funding into NK-focused biotech has exceeded $4.2 billion from 2020 to 2026, indicating strong investment enthusiasm and market potential, with GT Biopharma positioned to benefit from this trend as a key player.
- Market Outlook: North America is expected to capture 44% of the global NK cell therapy market by 2026, and GT Biopharma's clinical trials and financial status provide a solid foundation for growth in this rapidly evolving market.
See More
GT Biopharma Doses First Patient in GTB-5550 Clinical Trial
- Trial Launch: On May 14, 2026, GT Biopharma dosed the first patient in its Phase 1 trial for GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in cancer treatment, particularly for patients with prostate, ovarian, and pancreatic cancers.
- FDA Approval: The IND application for GTB-5550 received FDA clearance in February 2026, with the trial structured as a basket trial prioritizing enrollment of advanced cancer patients who have failed prior therapies, demonstrating the company's commitment to addressing unmet medical needs.
- Strong Financial Position: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, thereby enhancing investor confidence in the progress of the clinical trial.
- Significant Market Potential: Targeting the estimated $362 billion global solid tumor market, the B7-H3 antigen has attracted multiple pharmaceutical companies, indicating a rapidly rising clinical translation potential in this competitive landscape.
See More
GT Biopharma Reports Q2 2026 Financial Results
- Widening Net Loss: GT Biopharma reported a net loss of approximately $2.8 million for Q2 2026, a significant increase from the $800,000 loss in the same quarter of 2025, indicating pressure on cost control and market competitiveness.
- Cash Position: As of March 31, 2026, the company had approximately $9 million in cash and cash equivalents, which is anticipated to be sufficient to fund operations through Q4 2026, demonstrating short-term liquidity management capabilities.
- Financial Transparency: The financial information released by GT Biopharma includes historical earnings data and Seeking Alpha’s Quant Rating, aimed at enhancing investor understanding of the company's financial status, although current performance is poor, the company is striving to improve transparency to attract investment.
- Market Outlook Challenges: While the company has a certain level of liquidity assurance, the ongoing losses may undermine investor confidence, necessitating effective measures to improve financial performance to maintain market competitiveness.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
GT Biopharma Launches Clinical Trial for B7-H3 Targeted Therapy
- Trial Launch: GT Biopharma announced on May 14, 2026, that the first patient has been dosed in its Phase 1 dose-escalation trial of GTB-5550, a therapy targeting B7-H3 in solid tumors, marking a significant advancement in the company's oncology efforts.
- Innovative Targeting Mechanism: GTB-5550 is the third TriKE® molecule from GT Biopharma, utilizing subcutaneous administration to enhance patient convenience, particularly in prostate cancer where B7-H3 is expressed in over 90% of metastatic castration-resistant tumors.
- Market Potential Emerges: The rising interest in B7-H3 as an oncology target is underscored by GT Biopharma's trial progress alongside other companies like Summit Therapeutics and IDEAYA, indicating broad applicability of this target in cancer treatment.
- Strengthened Industry Collaborations: The partnership between Summit Therapeutics and GSK further validates the market value of B7-H3, with the combination study of GSK's antibody drug and Summit's bispecific antibody expected to begin in mid-2026, providing positive signals for investors.
See More
